(3S,4S)-1-tert-butoxycarbonyl-3-hydroxy-4-methylaminopyrrolidine | 429673-81-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (3S,4S)-1-tert-butoxycarbonyl-3-hydroxy-4-methylaminopyrrolidine
• 英文别名: tert-Butyl trans-3-hydroxy-4-methylaminopyrrolidin-1-carboxylate；(3S,4S)-tert-Butyl 3-hydroxy-4-(methylamino)pyrrolidine-1-carboxylate；tert-butyl (3S,4S)-3-hydroxy-4-(methylamino)pyrrolidine-1-carboxylate
• CAS: 429673-81-4
• 化学式: C₁₀H₂₀N₂O₃
• mdl: MFCD18072068
• 分子量: 216.28
• InChiKey: IJLLHXGWHBTSPV-YUMQZZPRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  61.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3S,4S)-1-tert-butoxycarbonyl-3-hydroxy-4-methylaminopyrrolidine 在 双(三甲基硅烷基)氨基钾 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 水 、 丙酮 为溶剂， 反应 3.0h， 生成 3-(tert-butoxycarbonyl-(methyl)-amino)-4-methoxy-pyrrolidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  [EN] STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION
  [FR] COMPOSITIONS STABLES DE SNS-595 ET PROCÉDÉS DE PRÉPARATION

  摘要：

  公开了制备基本纯净的SNS-595物质的方法。还提供了含有基本纯净且基本无可见颗粒的SNS-595物质的组合物。

  公开号：

  WO2011028979A1
• 作为产物：
  描述：

  (3S,4S)-1-tert-butoxycarbonyl-3-(N-tert-butoxycarbonyl-L-phenylalanyl)methylamino-4-hydroxypyrrolidine 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 7.0h， 以93%的产率得到(3S,4S)-1-tert-butoxycarbonyl-3-hydroxy-4-methylaminopyrrolidine
  参考文献：
  名称：

  Practical synthesis of (3S,4S)-3-methoxy-4-methylaminopyrrolidine

  摘要：

  Three synthetic methods for the preparation of (3S,4S)-3-methoxy-4-methylaminopyrrolidine, an important intermediate in the synthesis of the novel quinolone antitumor agent, AG-7352, have been developed. By one route, an efficient and large-scale preparation of the chiral pyrrolidine could be achieved through resolution of (+/-)-1-Boc-3-benzylamino-4-hydroxypyrrolidine, which is prepared from either 3-pyrroline or 1,4-dichloro-2-butene. (C) 2002 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0957-4166(01)00530-4

文献信息

• Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040220191A1

  公开（公告）日：2004-11-04

  The invention relates to substituted N-aryl heterocycles and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I 1 in which the radicals have the stated meanings, the N-oxides and the physiologically tolerated salts thereof and process for the preparation thereof are described. The compounds are suitable for example as anorectic agents.

  这项发明涉及取代N-芳基杂环化合物及其生理耐受盐和生理功能衍生物。式I的化合物 1 其中基团具有所述含义，其N-氧化物及其生理耐受盐以及其制备方法被描述。这些化合物例如适用作为厌食剂。
• Amide Derivative and Medicine
  申请人：Asaki Tetsuo

  公开号：US20080293940A1

  公开（公告）日：2008-11-27

  The present invention is directed to an amide derivative having excellent BCR-ABL tyrosine kinase inhibitory activity, or a salt thereof. The present invention provides an amide derivative represented by the following general formula (1): [Chemical 23] (wherein R 1 represents —CH 2 —R 11 , etc.; R 2 represents alkyl, halogen, haloalkyl, etc.; R 3 represents hydrogen, etc.; Het1 represents a group of the formula [6] as above, etc.; and Het2 represents pyrimidinyl, etc.), or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention is useful as a BCR-ABL tyrosine kinase inhibitor.

  本发明涉及具有优异的BCR-ABL酪氨酸激酶抑制活性的酰胺衍生物或其盐。本发明提供了由下述通式（1）表示的酰胺衍生物：[化学式23]（其中，R1代表—CH2—R11等；R2代表烷基、卤素、卤代烷基等；R3代表氢等；Het1代表如上所述的[6]式基团等；Het2代表嘧啶基等），或其药学上可接受的盐，并且提供了包含其作为活性成分的制药组合物。本发明的化合物在作为BCR-ABL酪氨酸激酶抑制剂方面是有用的。
• Imidazothiazole derivatives
  申请人：Kawato Haruko

  公开号：US20090312310A1

  公开（公告）日：2009-12-17

  There is provided a novel compound that inhibits interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity. The present invention provides an imidazothiazole derivative represented by the following formula (1) having various substituents that inhibits interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity: wherein R 1 , R 2 , R 3 , R 4 , and R 5 in the formula (1) each has the same meaning as defined in the specification.

  提供了一种新的化合物，它抑制小鼠双分子分钟2（Mdm2）蛋白与p53蛋白之间的相互作用，并展现出抗肿瘤活性。本发明提供了一种咪唑噻唑衍生物，其表示为以下公式（1），具有各种取代基，可抑制Mdm2蛋白与p53蛋白之间的相互作用并展现出抗肿瘤活性：其中，公式（1）中的R1、R2、R3、R4和R5每个都具有规范中定义的相同含义。
• Amide derivative and medicine
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：US07728131B2

  公开（公告）日：2010-06-01

  The present invention is directed to an amide derivative having excellent BCR-ABL tyrosine kinase inhibitory activity, or a salt thereof. The present invention provides an amide derivative represented by the following general formula (1): [Chemical 23] (wherein R1 represents —CH2—R11, etc.; R2 represents alkyl, halogen, haloalkyl, etc.; R3 represents hydrogen, etc.; Het1 represents a group of the formula [6] as above, etc.; and Het2 represents pyrimidinyl, etc.), or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention is useful as a BCR-ABL tyrosine kinase inhibitor.

  本发明涉及一种具有出色的BCR-ABL酪氨酸激酶抑制活性的酰胺衍生物或其盐。本发明提供了一种由下式（1）表示的酰胺衍生物：[化学式23]（其中，R1表示—CH2—R11等；R2表示烷基，卤素，卤代烷基等；R3表示氢等；Het1表示上述[6]式的基团等；Het2表示嘧啶基等），或其药学上可接受的盐，以及包含其作为活性成分的制药组合物。本发明的化合物可用作BCR-ABL酪氨酸激酶抑制剂。
• Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
  申请人：Sudhakar Anantha

  公开号：US20100203162A1

  公开（公告）日：2010-08-12

  Methods of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid are disclosed. Also provided are pharmaceutical compositions comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid, and methods of treatment using such compositions.

  本文披露了制备(+)-1,4-二氢-7-[(3S,4S)-3-甲氧基-4-(甲基氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法。同时，还提供了含有(+)-1,4-二氢-7-[(3S,4S)-3-甲氧基-4-(甲基氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的制药组合物，并且还提供了使用这种组合物进行治疗的方法。